These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15231507)

  • 1. How the type of risk reduction influences required sample sizes in randomised clinical trials.
    Bruynesteyn K; Wanders A; Landewé R; van der Heijde D
    Ann Rheum Dis; 2004 Nov; 63(11):1368-71. PubMed ID: 15231507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of underpowered randomized clinical trials in rheumatology.
    Keen HI; Pile K; Hill CL
    J Rheumatol; 2005 Nov; 32(11):2083-8. PubMed ID: 16265683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials.
    Hutton JL
    Br J Haematol; 2009 Jun; 146(1):27-30. PubMed ID: 19438480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primer: the fallacy of subgroup analysis.
    Guillemin F
    Nat Clin Pract Rheumatol; 2007 Jul; 3(7):407-13. PubMed ID: 17599075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance of dosimetry and the impact on sample size in randomized clinical trials.
    Pettersen MN; Aird E; Olsen DR
    Radiother Oncol; 2008 Feb; 86(2):195-9. PubMed ID: 17727987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based dermatology: number needed to treat and its relation to other risk measures.
    Manriquez JJ; Villouta MF; Williams HC
    J Am Acad Dermatol; 2007 Apr; 56(4):664-71. PubMed ID: 17367615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
    Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
    J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials.
    Yuen SY; Pope JE
    Rheumatology (Oxford); 2008 Sep; 47(9):1367-72. PubMed ID: 18577549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale randomised trials--a misguided approach to clinical research.
    Penston J
    Med Hypotheses; 2005; 64(3):651-7. PubMed ID: 15617882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised controlled trials in overweight children: practicalities and realities.
    Warren JM; Golley RK; Collins CE; Okely AD; Jones RA; Morgan PJ; Perry RA; Baur LA; Steele JR; Magarey AM
    Int J Pediatr Obes; 2007; 2(2):73-85. PubMed ID: 17763014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of a registry database in clinical trial design: assessing the influence of entry criteria on statistical power and number of eligible patients.
    Peelen L; Peek N; de Jonge E; Scheffer GJ; de Keizer NF
    Int J Med Inform; 2007; 76(2-3):176-83. PubMed ID: 16829179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design considerations for randomised trials in orthopaedic fracture surgery.
    Simunovic N; Devereaux PJ; Bhandari M
    Injury; 2008 Jun; 39(6):696-704. PubMed ID: 18502423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Are patients in randomised controlled trials of psychotherapy representative for clinical practice?].
    Vanwezer K; Pieters G
    Tijdschr Psychiatr; 2009; 51(3):183-7. PubMed ID: 19536974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trials--cluster versus individual randomisation. Primary Care Alliance for Clinical Trials (PACT) network.
    Elley CR; Chondros P; Kerse NM
    Aust Fam Physician; 2004 Sep; 33(9):759-63. PubMed ID: 15487374
    [No Abstract]   [Full Text] [Related]  

  • 20. How many do I need? Basic principles of sample size estimation.
    Devane D; Begley CM; Clarke M
    J Adv Nurs; 2004 Aug; 47(3):297-302. PubMed ID: 15238124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.